Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance

Current Opinion in Pharmacology

Volumn 12, Issue 5, 2012, Pages 551-555

  Pieren, Michel ^a   Tigges, Marcel ^a  

^a BIOVERSYS AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYL ETHYL BUTYRATE DERIVATIVE; AMIDE; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BDM 31343; BENZIMIDAZOLE DERIVATIVE; BETA LACTAM ANTIBIOTIC; BIRICODAR; BUTYRIC ACID DERIVATIVE; CLAVULANIC ACID; DIPEPTIDE; ETHIONAMIDE; HYDROXYBENZIMIDAZOLE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; OXADIAZOLE DERIVATIVE; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; PHENYLALANYLARGINYL BETA NAPHTHYLAMIDE; REPRESSOR PROTEIN; THIOPHEN 2 YL 1,2,4 OXADIAZOLE; TOBRAMYCIN; TRIMETHOPRIM; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRSTATIN; WALRYCIN A; WALRYCIN B;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUBERCULOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84867332729     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.07.005     Document Type: Review

References (52)

1. O. Cars, A. Hedin, and A. Heddini The global need for effective antibiotics-moving towards concerted action Drug Resist Updat 14 2011 68 69
2. J. Davies, and D. Davies Origins and evolution of antibiotic resistance Microbiol Mol Biol Rev 74 2010 417 433
3. A. Nijnik, and R. Hancock Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections Emerg Health Threats J 2 2009 1 7
4. M.J. McConnell, J. Domínguez-Herrera, Y. Smani, R. López-Rojas, F. Docobo-Pérez, and J. Pachón Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii Infect Immun 79 2011 518 526
5. N. Ni, M. Li, J. Wang, and B. Wang Inhibitors and antagonists of bacterial quorum sensing Med Res Rev 29 2009 65 124
6. J. Ter Meulen Monoclonal antibodies in infectious diseases: clinical pipeline in 2011 Infect Dis Clin North Am 25 2011 789 802
7. K.R. Allison, M.P. Brynildsen, and J.J. Collins Heterogeneous bacterial persisters and engineering approaches to eliminate them Curr Opin Microbiol 14 2011 593 598
8. S.T. Abedon, and C. Thomas-Abedon Phage therapy pharmacology Curr Pharm Biotechnol 11 2010 28 47
9. W. Weber, R. Schoenmakers, B. Keller, M. Gitzinger, T. Grau, M. Daoud-El Baba, P. Sander, and M. Fussenegger A synthetic mammalian gene circuit reveals antituberculosis compounds Proc Natl Acad Sci USA 105 2008 9994 9998
10. J. Fernebro Fighting bacterial infections-future treatment options Drug Resist Updat 14 2011 125 139
11. U. Theuretzbacher Resistance drives antibacterial drug development Curr Opin Pharmacol 11 2011 6 11
12. M.N. Alekshun, and S.B. Levy Molecular mechanisms of antibacterial multidrug resistance Cell 128 2007 1037 1050
13. D.I. Andersson, and D. Hughes Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8 2010 260 271
14. F. Depardieu, I. Podglajen, R. Leclercq, E. Collatz, and P. Courvalin Modes and modulations of antibiotic resistance gene expression Clin Microbiol Rev 20 2007 79 114
15. M.A. Fischbach Combination therapies for combating antimicrobial resistance Curr Opin Microbiol 14 2011 519 523
16. L. Ejim, M.A. Farha, S.B. Falconer, J. Wildenhain, B.K. Coombes, M. Tyers, E.D. Brown, and G.D. Wright Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy Nat Chem Biol 7 2011 348 350
17. K. Wuichet, B.J. Cantwell, and I.B. Zhulin Evolution and phyletic distribution of two-component signal transduction systems Curr Opin Microbiol 13 2010 219 225
18. Y. Gotoh, A. Doi, E. Furuta, S. Dubrac, Y. Ishizaki, M. Okada, M. Igarashi, N. Misawa, H. Yoshikawa, and T. Okajima Novel antibacterial compounds specifically targeting the essential WalR response regulator J Antibiot 63 2010 127 134
19. H.T. Nguyen, K.A. Wolff, R.H. Cartabuke, S. Ogwang, and L. Nguyen A lipoprotein modulates activity of the MtrAB two-component system to provide intrinsic multidrug resistance, cytokinetic control and cell wall homeostasis in Mycobacterium Mol Microbiol 76 2010 348 364
20. E.C. Theodorou, M.C. Theodorou, and D.A. Kyriakidis Inhibition of the signal transduction through the AtoSC system by histidine kinase inhibitors in Escherichia coli Cell Signal 23 2011 1327 1337
21. A. Okada, M. Igarashi, T. Okajima, N. Kinoshita, M. Umekita, R. Sawa, K. Inoue, T. Watanabe, A. Doi, and A. Martin Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth J Antibiot 63 2010 89 94
22. M. Kostakioti, M. Hadjifrangiskou, J.S. Pinkner, and S.J. Hultgren QseC-mediated dephosphorylation of QseB is required for expression of genes associated with virulence in uropathogenic Escherichia coli Mol Microbiol 73 2009 1020 1031
23. T. Miyashiro, and M. Goulian Stimulus-dependent differential regulation in the Escherichia coli PhoQ-PhoP system Proc Natl Acad Sci USA 104 2007 16305 16310
24. A. Brencic, K.A. McFarland, H.R. McManus, S. Castang, I. Mogno, S.L. Dove, and S. Lory The GacS/GacA signal transduction system of Pseudomonas aeruginosa acts exclusively through its control over the transcription of the RsmY and RsmZ regulatory small RNAs Mol Microbiol 73 2009 434 445
25. S. Lee, A. Hinz, E. Bauerle, A. Angermeyer, K. Juhaszova, Y. Kaneko, P.K. Singh, and C. Manoil Targeting a bacterial stress response to enhance antibiotic action Proc Natl Acad Sci USA 106 2009 14570 14575
26. T.E. Bowser, V.J. Bartlett, M.C. Grier, A.K. Verma, T. Warchol, S.B. Levy, and M.N. Alekshun Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors Bioorg Med Chem Lett 17 2007 5652 5655
27. L.K. Garrity-Ryan, O.K. Kim, J.-M. Balada-Llasat, V.J. Bartlett, A.K. Verma, M.L. Fisher, C. Castillo, W. Songsungthong, S.K. Tanaka, and S.B. Levy Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model Infect Immun 78 2010 4683 4690
28. E.A. Shakhnovich, D.T. Hung, E. Pierson, K. Lee, and J.J. Mekalanos Virstatin inhibits dimerization of the transcriptional activator ToxT Proc Natl Acad Sci USA 104 2007 2372 2377
29. A. Zumla, I. Abubakar, M. Raviglione, M. Hoelscher, L. Ditiu, T. McHugh, S. Squire, H. Cox, N. Ford, and R. McNerney Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs J Infect Dis 205 2012 S228 S240
30. N. Willand, B. Dirié, X. Carette, P. Bifani, A. Singhal, M. Desroses, F. Leroux, E. Willery, V. Mathys, and R. Déprez-Poulain Synthetic EthR inhibitors boost antituberculous activity of ethionamide Nat Med 15 2009 537 544
31. M. Flipo, M. Desroses, N. Lecat-Guillet, B. Dirié, X. Carette, F. Leroux, C. Piveteau, F. Demirkaya, Z. Lens, and P. Rucktooa Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors J Med Chem 54 2011 2994 3010
32. F. Frenois, A. Baulard, and V. Villeret Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis Tuberculosis 86 2006 110 114
33. S.M. Drawz, and R.A. Bonomo Three decades of β-lactamase inhibitors Clin Microbiol Rev 23 2010 160 201
34. M.G.P. Page, C. Dantier, and E. Desarbre In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli Antimicrob Agents Chemother 54 2010 2291 2302
35. F. Wang, C. Cassidy, and J.C. Sacchettini Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics Antimicrob Agents Chemother 50 2006 2762 2771
36. C. Sala, A. Haouz, F.A. Saul, I. Miras, I. Rosenkrands, P.M. Alzari, and S.T. Cole Genome-wide regulon and crystal structure of BlaI (Rv1846c) from Mycobacterium tuberculosis Mol Microbiol 71 2009 1102 1116
37. J.-E. Hugonnet, L.W. Tremblay, H.I. Boshoff, C.E. Barry, and J.S. Blanchard Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis Science 323 2009 1215 1218
38. N. Dauby, I. Muylle, F. Mouchet, R. Sergysels, and M.-C. Payen Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis Pediatr Infect Dis J 30 2011 812 813
39. M.S. Ramirez, and M.E. Tolmasky Aminoglycoside modifying enzymes Drug Resist Updat 13 2010 151 171
40. K. Vong, I.S. Tam, X. Yan, and K. Auclair Inhibitors of aminoglycoside resistance activated in cells ACS Chem Biol 2012 10.1021/cb200366u
41. M. Feder, E. Purta, L. Koscinski, S. Cubrilo, G. Maravic Vlahovicek, and J.M. Bujnicki Virtual screening and experimental verification to identify potential inhibitors of the ErmC methyltransferase responsible for bacterial resistance against macrolide antibiotics Chemmedchem 3 2008 316 322
42. F. Van Bambeke, Y. Glupczynski, P. Plésiat, J.C. Pechère, and P.M. Tulkens Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy J Antimicrob Chemother 51 2003 1055 1065
43. J.-M. Pagès, and L. Amaral Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria Biochim Biophys Acta 1794 2009 826 833
44. L.J.V. Piddock, M.I. Garvey, M.M. Rahman, and S. Gibbons Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria J Antimicrob Chemother 65 2010 1215 1223
45. O. Lomovskaya, M.S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, and T. Renau Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy Antimicrob Agents Chemother 45 2001 105 116
46. A.Y. Coban, B. Ekinci, and B. Durupinar A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates Chemotherapy 50 2004 22 26
47. J. Chevalier, J. Bredin, A. Mahamoud, M. Malléa, J. Barbe, and J.-M. Pagès Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains Antimicrob Agents Chemother 48 2004 1335 1343
48. S. Mullin, N. Mani, and T.H. Grossman Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853) Antimicrob Agents Chemother 48 2004 4171 4176
49. G.M. Eliopoulos, and R.C. Moellering Antibiotic synergism and antimicrobial combinations in clinical infections Rev Infect Dis 4 2011 282 293
50. R. Chait, A. Craney, and R. Kishony Antibiotic interactions that select against resistance Nature 446 2007 668 671
51. J.P. Torella, R. Chait, and R. Kishony Optimal drug synergy in antimicrobial treatments PLoS Comput Biol 6 2010 9
52. T.M. Powledge New antibiotics - resistance is futile PLoS Biol 2 2004 E53